Keros Therapeutics Inc’s recently made public that its Affiliate Rovaldi Christopher acquired Company’s shares for reported $1.34 million on Sep 12 ’25. In the deal valued at $15.71 per share,85,306 shares were bought.
Then, ADAR1 Capital Management, LLC bought 934,258 shares, generating $9,464,512 in total proceeds. Upon buying the shares at $10.13, the 10% Owner now owns 4,392,737 shares.
BofA Securities downgraded its Keros Therapeutics Inc [KROS] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who decreased its forecast for the stock in late January from “an Overweight” to “a Neutral”. Wedbush also remained covering KROS and has decreased its forecast on January 17, 2025 with a “Neutral” recommendation from previously “an Outperform” rating. Oppenheimer maintained its rating on December 16, 2024. It rated KROS as “an Outperform”.
Price Performance Review of KROS
On Friday, Keros Therapeutics Inc [NASDAQ:KROS] saw its stock fall -2.99% to $15.56. Over the last five days, the stock has lost -0.64%. Keros Therapeutics Inc shares have fallen nearly -71.73% since the year began. Nevertheless, the stocks have fallen -1.71% over the past one year.
How much short interest is there in Keros Therapeutics Inc?
A steep rise in short interest was recorded in Keros Therapeutics Inc stocks on 2025-08-29, dropping by -0.34 million shares to a total of 4.5 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 4.84 million shares. There was a decline of -7.55%, which implies that there is a negative sentiment for the stock.
